Navigation Links
Genta Receives Notice of Non-Compliance With NASDAQ Rule
Date:1/11/2008

Company to File Appeal

BERKELEY HEIGHTS, N.J., Jan. 11 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company has received notice from the Listing Qualifications Staff of The NASDAQ Stock Market that, based upon the Company's non-compliance with the stockholders' equity requirement set forth in NASDAQ Marketplace Rule 4450(a)(3), the Company's common stock is subject to delisting from The NASDAQ Global Market unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel. The Staff's letter follows prior correspondence from NASDAQ regarding the Company's stockholders' equity balance, which was previously disclosed in the Company's press release dated November 16, 2007.

The Company plans to timely request a hearing before the Panel, which will stay any delisting action until the Panel renders a decision subsequent to the hearing. The Company anticipates that the hearing will be scheduled within the next 45 days.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cance
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... A new clinical study presented to the Am...t three-dimensional (3-D) automated ultrasound fol...ng an in vitro fertilization (IVF) cycle is effect...surement of the follicles. , ...anced Fertility Center of Chicago has just complet...
(Date:12/1/2009)... Michael R. Drapp, a 34-year veteran of t...rade; Technologies, a business development and int...he emerging nanotechnology space. The company als...t as a nanotechnology incubator. , ... Michael R. Drapp , a 34-year veteran of the high...
(Date:11/30/2009)...MINGTON, Minn., Nov. 30 Acuo Techn...age management software, data migration tools and ...Hospitals and Clinics for a new Vendor Neutral Arc...age across the Allina network of hospitals, clinic...based on the Acuo Technologies DICOM Services Grid...
(Date:11/30/2009)... AMSTERDAM, November 30 Biopharmac... the first patients have been enrolled in its,mult...). The study is,designed to show reduction in tran...owing an allogeneic stem cell transplantation with...cer patients eligible for an allogeneic,stem cell ...
Breaking Biology Technology:Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 2Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2
...HILADELPHIA, Pennsylvania and DUBLIN, Ireland, Feb...he global,specialty biopharmaceutical company anno...a year which has seen significant growth in Shire,...s, Full Year 200... $2.75bn + 27% $0.70 bn + 7%...
...ogen board; , , - finally accepts legitima...ing; , , - will not allow shareholder vote... with high risk, high funding, Avexa merger propos...th refusal to align meeting dates , , Shareholder...RNE, Australia, Feb. 19 A general meeting of Prog...
...res Quarterly Dividend , , ACTON, Mass., Feb. 18 ...nnounced fourth quarter and year-end financial res...Company also announced a quarterly dividend of $0....of March 6, 2009 to be paid on March 20, 2009. Th...y dividend. , , The Company,s revenue for the yea...
Other Biology Technology:Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 2Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 3Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 4Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 5Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 6Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 7Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 8Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 9Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 10Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 11Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 12Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 13Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 14Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 15Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 16Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 17Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 18Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 19Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 20Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 21Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 22Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 23Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 24Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 25Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 26Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 27Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 28Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 29Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 30Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 31Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 32Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion 33Progen Concedes Shareholder Requisitioned Meeting 2Progen Concedes Shareholder Requisitioned Meeting 3Progen Concedes Shareholder Requisitioned Meeting 4
(Date:11/30/2009)... German . , The DFG has approved the establi... of 1 January 2010. This decision was made recentl...w centres will initially be funded for four years ...nt overhead funding for indirect costs will also b... topics range from modern prostheses to political ...
(Date:11/30/2009)... Global Conference on Systems & Enterprises (GCSE)..., focuses on the convergence of complex large-scal...o society. , The goal of the conference is t...rgeted complex systems, examined by domain, each s...al Infrastructure Systems, including Intelligent/S...
(Date:11/30/2009)...ch is the virus,s exquisite specialisation for its...tools, like the humble lab mouse, can deliver only...riting in BioMed Central,s open access Journal of...roblem by creating a mouse that has key features o..., George Kassiotis, from the Division of Immunore...
Breaking Biology News(10 mins):DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2A reductionist approach to HIV research 2Initial Slate of Speakers and Sponsors Announced for BioConference Live Online Conference for the Life Science Community on November 17 19 56763 1Initial Slate of Speakers and Sponsors Announced for BioConference Live Online Conference for the Life Science Community on November 17 19 56763 2Initial Slate of Speakers and Sponsors Announced for BioConference Live Online Conference for the Life Science Community on November 17 19 56763 3New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 1New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 2New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 3New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 4New Mobile STAR Cranial Center of Excellence Vehicle Brings Cutting Edge Treatment to Satellite Communities 56758 5Access Pharmaceuticals Provides Update on ProLindac 28TM 29Clinical Development Plan 13977 1Access Pharmaceuticals Provides Update on ProLindac 28TM 29Clinical Development Plan 13977 2Access Pharmaceuticals Provides Update on ProLindac 28TM 29Clinical Development Plan 13977 3Access Pharmaceuticals Provides Update on ProLindac 28TM 29Clinical Development Plan 13977 4
...orhiza punctata, first reported in great quantitie...us reappearance this summer in waters from southwe... Beachgoers and boaters are encouraged to report t...hin Island Sea Labs jellyfish website, Dockwatch, ...llorhiza sightings have occurred in the Gulf as fa...
...tinely added to consumer products from carpets to ...ealth officials, however, are concerned that one c...enylethers (PBDEs), may be doing more than reducin...fter several decades of use, PBDEs are widely dist...ace levels of these chemicals can be measured in a...
...echnology (NIST) has issued a suite of Standard Re... the most popular dietary supplements in the marke...1 billion. , The NIST reference materials are de...f analytical methods for flavonoids and terpene la...with the perceived effectiveness of ginkgo) as wel...
Other Biology News:Invasive Australian jellyfish sighted in Gulf of Mexico in summer 2007 2SRMs track fire retardants in humans and environment 2Ginkgo SRMs: Tools for product analysis/quality 2
Taq DNA Polymerase (Thermus aquaticus) from GE Healthcare, formerly Amersham Biosciences
AmpliTaq DNA Polymerase with Buffer II from Applied Biosystems
AmpliTaq DNA Polymerase with Buffer I from Applied Biosystems
Mango-Taq DNA Polymerase from Bioline
Biology Products: